Daniel

HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases

by

Series A round led by Sofinnova Partners and Earlybird Venture Capital with syndicate including Eli Lilly and Company Funds to advance clinical development of heart failure lead candidate and expand platform targeting the regulatory genome ‍LAUSANNE, Switzerland and SAN DIEGO, USA – May 8, 2025 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory … Read more

Distalmotion Advances US Expansion of its DEXTER® Surgical Robot with Clinical Milestones and System Enhancements

by

Distalmotion, the global MedTech company empowering access to the benefits of robotic surgery, progresses on the path to expand its US footprint with the completion of cholecystectomy and benign hysterectomy clinical trials – to support 510(k) pre-market submissions for additional indications – and product enhancements to further increase procedural fluidity and wristed instrument dexterity. The … Read more

DEXTER® Robotic Surgery System by the First Ambulatory Surgery Center in the US

by

Two patients were treated for inguinal hernia repair using Distalmotion’s Dexter® Robotic Surgery System within 30 days of FDA De Novo Northtowns Ambulatory Surgery Center (ASC), a joint venture between Buffalo surgeons and Kaleida Health Ventures, has chosen Distalmotion’s DEXTER® Robotic Surgery System as its outpatient surgical robot of choice, marking a major milestone in … Read more

Dexter® Robotic Surgery System in the Outpatient Setting

by

Two patients were treated for inguinal hernia repair using Distalmotion’s Dexter® Robotic Surgery System within 30 days of FDA De Novo marketing authorization. Less than 30 days after receiving FDA De Novo marketing authorization, Distalmotion’s Dexter Robotic Surgery System has successfully treated the first US patients in an outpatient setting. Two adult inguinal hernia repairs … Read more

HAYA Therapeutics Awarded Innosuisse Certificate for Sustainable Growth and Funding to Advance Treatment for Aggressive Solid Tumors

by

Former Exscientia executive who helped build the company and facilitate its merger with Recursion Pharmaceuticals joins to accelerate HAYA’s Non-dilutive funding of 1.5M CHF will be used to develop a novel therapy targeting cancer-associated fibroblast-specific long non-coding RNA (lncRNA)‍ LAUSANNE, Switzerland and SAN DIEGO, USA – Feb. 12, 2025 – HAYA Therapeutics, SA, a biotechnology company … Read more

Putting innovation at the heart of RNA-based therapeutics

by

Working towards a crucial breakthrough in the way we treat disease: HAYA Therapeutics aims to revolutionise patients treatments by focusing on Dark Genome-derived RNAs, now recognised as the ‹Regulatory Genome› RNAs. Thanks to its innovative approach, the company has attracted the attention of American pharmaceutical giant Eli Lilly. HAYA Therapeutics, which is supported by Innosuisse, is capitalising … Read more

First Patients in U.S. Treated with Distalmotion’s Dexter Surgical Robot in the Outpatient Setting

by

October 28 , 2024 Distalmotion’s Dexter Surgical Robot opens an entire new era for soft tissue robotics in the outpatient setting and ambulatory surgery centers that will have immediate benefit for patients. ​​​ ​​​Distalmotion has been granted De Novo approval by the U.S. Food and Drug Administration (FDA) to market the Dexter Surgical Robot for … Read more

EP #453 – Samir Ounzain: Unlocking the Power of the Dark Genome

by

This episode was sponsored by ⁠smzh⁠, your independent go-to partner in all matters relating to finance. About Samir Ounzain: ⁠Samir Ounzain⁠ is the co-founder and CEO of ⁠HAYA Therapeutics⁠, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at … Read more

Reprogramming the software of the cell to fight disease

by

HAYA Therapeutics is using its unparalleled regulatory genome atlas and innovative proprietary platform to identify novel long non-coding RNAs and develop drug candidates that return diseased cells back to healthy states. Heart failure and many other common and chronic diseases that have a huge impact on society can be driven by lifestyle-related risk factors. A … Read more

FDA Grants De Novo Marketing Authorization for the Distalmotion Dexter® Surgical Robot

by

October 28 , 2024 Distalmotion, a pioneer in surgical robotics, proudly announces the achievement of a significant milestone: surpassing 1000 successful procedures with its surgical robot, Dexter. Since its first commercial installation in 2022, Dexter has become a cornerstone in surgical innovation, treating patients everyday across multiple countries and institutions. ​​​ Distalmotion has been granted … Read more

daniel bertholet

4seeventures 

Chemin Falletti 6 C

1224 Chêne-Bougeries

Copyright © 2024

terms of service PRIVACY POLICY